# PAPMET (NCT02761057)

> Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02761057
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
- Interventions: Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Crizotinib; Savolitinib; Sunitinib Malate
- Enrollment: 152
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on PAPMET so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 42
- YouTube: 24
- Podcasts: 11
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=papmet-nct02761057

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02761057", "email": "<work email>"}; the inbox owner confirms by the emailed link.